Tuberculin ; Philippines

Tuberculin Test

No abstract available.
Tuberculin Test ; Tuberculosis*

We conducted tuberculin test with tuberculin 2UI 0,1ml PPD 23 Tween 80 by Copenhagen among 250 children who had BCG immunization after 3 months. The results of study: the positive rate of tuberculin test was 62%, 51.2% diameter of positive reaction was 6-10 mm. The positive rate of tuberculin test among the children who had breast feeding was higher among the rest group children (65.8% vs. 51.5%). Age of children when injection (during the first three months), weight of birth, a way of delivery did not influence to the positive rate of tuberculin test.
Tuberculin ; Child ; Mycobacterium bovis

Background: Verruca vulgaris ranked 10th in the top 10 diseases in 2019 seen among the Philippine Dermatological Society training institutions. The efficacy of immunotherapy, such as intralesional zinc sulfate (ZS), for warts were reported. Considering the limited studies with promising results on verruca, a study on the efficacy and safety of intralesional zinc in the treatment of verruca was considered. Objective: This study aims to determine the efficacy and safety of intralesional 2% ZS in comparison to intralesional purified protein derivative (PPD) among adult patients with verruca vulgaris. Methods: This is a double-blind, randomized, controlled trial involving 44 patients allocated to group ZS (n=22) and PPD (n=22). Intralesional injections of ZS or PPD to the largest wart were done at weeks 0, 2, 4, 6, 8, 10. Clearance and size reduction of the target and distant wart at 12th week and recurrence at 14th week were assessed. Adverse effects were checked. Results: At the 12th week of treatment, higher proportion in group ZS patients achieved total resolution of the target lesion compared to PPD, but results were not statistically significant (29% vs. 19%). Both groups showed decline in the target lesion size. The median size reduction between the two groups showed no significant differences. Three patients from group ZS showed clearance of distant warts while none in group PPD. There was no recurrence of all previously resolved warts. Adverse reactions were pain, edema, and erythema. Conclusion Intralesional 2% zinc sulfate (29%) was efficacious and safe compared to Intralesional PPD (19%) but the difference was not statistically significant. There was clearance of distant warts in 5% of group ZS patients. The mild adverse events did not warrant discontinuation of treatment.
Zinc Sulfate ; Tuberculin

Introduction: Intralesional purified protein derivative (PPD) is an affordable therapeutic option that has been studied for cutaneous warts. However, the lack of good evidence precludes its widespread use. Objective: To determine the efficacy and safety of intralesional PPD in the treatment of cutaneous warts. Methods: A systematic search for controlled clinical trials comparing intralesional PPD and placebo or any conventional therapy was conducted using electronic databases. The included studies were assessed for risk of bias, and data such as clearance rate of target and distant lesions, recurrence rate, and adverse events were extracted. Analysis was done through RevMan v5.3. Results: Four controlled clinical trials composed of 205 patients were included. All of the studies compared intralesional PPD to placebo as comparator. Intralesional PPD had a significantly higher clearance rate of target wart (RR=0.43[0.22,0.84], P=0.01) and a significantly higher clearance rate of distant lesions (RR=0.59[0.41,0.85], P=0.005) as compared to placebo. However, there was no significant difference in the recurrence rate (RR=0 [-0.07,0.07], P=0.98). Adverse events reported were only considered minor. Conclusion Intralesional PPD is an effective and safe treatment option for cutaneous warts. However, more well-structured RCTs with longer follow-up period and those comparing it with conventional treatment are needed to further support its use.
Warts ; Meta-Analysis ; Tuberculin

No abstract available.
Child* ; Humans ; Mycobacterium bovis* ; Skin* ; Tuberculin Test* ; Tuberculin*

Summary Despite a variety of therapeutic options that is available, treatment of warts remains challenging and rate of recurrence is high. Intralesional immunotherapy is an emerging therapy for warts. Tuberculin purified protein derivative (PPD) is one of the immunotherapeutic antigens used for the treatment of warts. Here we report a case of recalcitrant periungual wart successfully treated with tuberculin immunotherapy.
Tuberculin--therapeutic use ; Wart--therapy

The Monotest was compared with the Mantoux test. A total of 527 first grade primary school children were subjected to test. Each child was innoculated simultaneously to one side arm with protein purified derivatve(PPD, 1TU) and to the another side arm with Monovac(Institute Merieux). Results from each test were read seperately 72 hours after administration. When induration of 2mm or greater was considered a positive Monotest reaction and compared to a positive Mantoux reaction of 10mm or greater, the sensitivity of Monotest to mantoux test was 96.19% and the specificity was 88.39%. When induration of 5mm or greater was considered a positive Monotest reaction and compared to a positive Mantoux reaction of 10mm or greater, the sensitivity of Monotesto to to Mantoux test was 81.90% and the specificity was 96.68%. From this results I would assume that the Monovac test can be substituted for Mantoux test(PPd, 1TU), preferably 2mm or greater swelling of Monovacc test is considered as a positive result.
Arm ; Child ; Humans ; Sensitivity and Specificity ; Tuberculin*

The warts are benign skin tumors caused by virus, most frequently seen in childhood, and have atendency to regress before reaching adulthood. Various articles have been suggested that wart involution may be involved with immune response of the host, but definite mechanism has not been found. The author studied the tuberculin sensitivities of the wart patients in order to evaluate immune responses of the hosts, and observed the course of the warts after BCG vaccination to the patients for the facilitation of nonspecific immune reaction of the hosts. The results are as follows; 1. Tuberculin positivity was not decreased, however the sensitivity to the tuberculin was decreased among the wart patients than the non-wart groups. 2. No significant difference was observed between the numbers of wart and the degrees of tuberculin sensitivity. R. BCG vaccination was promoted the invotution of warts without valuable changes of the tuberculin sensitivities.
Humans ; Mycobacterium bovis* ; Skin ; Tuberculin* ; Vaccination* ; Warts*